ESC2025 Premium Access

Impact of elevated lipoprotein(a) on LDL-C lowering efficacy in ACS patients undergoing triple lipid-lowering therapy: insights from LAI-REACT-LP(a) sub-study

Congress Presentation

About the speaker

Doctor Kunal Mahajan

Himachal Heart Institute, Himachal Pradesh (India)
0 follower

5 more presentations in this session

Frequency of gout adverse events with bempedoic acid or placebo in those receiving uric acid lowering therapies as prophylaxis or treatment after a gout episode - insights from CLEAR outcomes

Speaker: Professor K. Ray (London, GB)

Thumbnail

Efficacy and safty of a quadruple combination of amlodipine, losartan, rosuvastatin, and ezetimibe in ASCVD patients with poor medication adherence (AMOREMIO study)

Speaker: Assistant Professor M. Chon (Yangsan, KR)

Thumbnail

Resistance to lipid-lowering therapy with PCSK9 inhibitors: comparative efficacy and clinical implications

Speaker: Assistant Professor W. Streb (Zabrze, PL)

Thumbnail

Efficacy and safety of pemafibrate in patients with statin-intolerant hypercholesterolemia: results from a 12-week, randomized, double blind, placebo-controlled, phase 3 trial

Speaker: Professor S. Yamashita (Izumisano, JP)

Thumbnail

Triple oral lipid-lowering treatment pathway and associated outcomes in high- and very high-cv risk patients: a simulation using the SANTORINI study cohort

Speaker: Doctor J. Katzmann (Leipzig, DE)

Thumbnail

Access the full session

Refining efficacy and safety of lipid-lowering pharmacotherapy

Speakers: Doctor K. Mahajan, Professor K. Ray, Assistant Professor M. Chon, Assistant Professor W. Streb, Professor S. Yamashita...
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations